Olawade, David ORCID: https://orcid.org/0000-0003-0188-9836, Oisakede, Emmanuel O., Egbon, Eghosasere, Ovsepian, Saak V. ORCID: https://orcid.org/0000-0002-9522-4159 and Boussios, Stergios ORCID: https://orcid.org/0000-0002-2512-6131 (2025) Immune Organoids: A Review of Their Applications in Cancer and Autoimmune Disease Immunotherapy. Current Issues in Molecular Biology, 47 (8). p. 653.

Preview

Text cimb-47-00653-v2.pdf - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Immune organoids have emerged as a ground-breaking platform in immunology, offering a physiologically relevant and controllable environment to model human immune responses and evaluate immunotherapeutic strategies. Derived from stem cells or primary tissues, these three-dimensional constructs recapitulate key aspects of lymphoid tissue architecture, cellular diversity, and functional dynamics, providing a more accurate alternative to traditional two-dimensional cultures and animal models. Their ability to mimic complex immune microenvironments has positioned immune organoids at the forefront of cancer immunotherapy development, autoimmune disease modeling, and personalized medicine. This narrative review highlights the advances in immune organoid technology, with a focus on their applications in testing immunotherapies, such as checkpoint inhibitors, CAR-T cells, and cancer vaccines. It also explores how immune organoids facilitate the study of autoimmune disease pathogenesis with insights into their molecular basis and support in high-throughput drug screening. Despite their transformative potential, immune organoids face significant challenges, including the replication of systemic immune interactions, standardization of fabrication protocols, scalability limitations, biological heterogeneity, and the absence of vascularization, which restricts organoid size and maturation. Future directions emphasize the integration of immune organoids with multi-organ systems to better replicate systemic physiology, the development of advanced biomaterials that closely mimic lymphoid extracellular matrices, the incorporation of artificial intelligence (AI) to optimize organoid production and data analysis, and the rigorous clinical validation of organoid-derived findings. Continued innovation and interdisciplinary collaboration will be essential to overcome existing barriers, enabling the widespread adoption of immune organoids as indispensable tools for advancing immunotherapy, vaccine development, and precision medicine.

Item Type:	Article
Status:	Published
DOI:	10.3390/cimb47080653
School/Department:	London Campus
URI:	https://ray.yorksj.ac.uk/id/eprint/12523

University Staff: Request a correction | RaY Editors: Update this record